Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 28;17:294. doi: 10.1186/s12967-019-2035-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 2 — Kaplan-Meier survival analysis of stage IV NSCLC cohort. a Baseline HD-CTC enumeration did not significantly affect OS. b Baseline HD-CTC enumeration did not significantly affect PFS. c Patients with > 2.0 CTC-Small cells/mL at baseline have a significantly shorter OS. d Patients with > 12.5 CTC-NoCytokeratin cells/mL at baseline have a significantly shorter OS. e Patients receiving bevacizumab with > 70.0 HD-CTCs/mL at baseline have a significantly shorter OS. f Patients with > + 4.6 Δ HD-CTCs/mL from the first to second blood draw have a significantly shorter OS. g Patients with > + 1.0 Δ HD-CTCs/mL from the first to last blood draw have a significantly shorter OS. LoET: lesser or equal to. The number of at risk individuals per group is shows below each graph